Relationship between GH/IGF-1 axis, graft recovery, and early survival in patients undergoing liver transplantation

What Was Tested

The paper reports a study of IGF-1 LR3, published as a clinical trial.

To evaluate the GH/IGF-1 profile as a function of liver recovery and patients' early survival after LT.

Why It Was Studied

High levels of IGF-1 have been reported in patients with initial poor function of the graft after liver transplantation (LT).

Correlation with other clinical variables or early survival has not been extensively investigated.

Who Took Part

According to the abstract, 30 patients were involved.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

30 transplanted patients (23 survivors and 7 nonsurvivors), were retrospectively enrolled in the study.

How the Study Was Run

GH and IGF-1 serum levels were assessed at baseline, graft reperfusion, and 1, 7, 15, 30 , 90, and 360 days after LT.

Individual biochemical variables were also recorded.

What Was Measured

High levels of IGF-1 have been reported in patients with initial poor function of the graft after liver transplantation (LT).

PubMed files the paper under topics including Disease-Free Survival, Graft Survival, Human Growth Hormone, Insulin-Like Growth Factor I, Liver, Liver Transplantation and Recovery of Function.

What This Means in Plain Language

This is a clinical trial of IGF-1 LR3 in 30 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (BioMed research international), a journal based in United States.

More context: the IGF-1 LR3 compound page, all human trials.